# A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

> **NCT02367066** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** AR-C165395XX
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02367066
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367066, "A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02367066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*